Zydus Lifesciences reported a consolidated net profit of ₹1,042.1 crore in Q3 FY26, up 1.8% from ₹1,023.5 crore a year ago, though down 17.2% sequentially.
Revenue jumped 32.4% year-on-year to ₹6,780.4 crore, driven by strong performance across key markets. EBITDA rose 31% to ₹1,816.4 crore, with margins improving to 26.5%. Segment-wise, North America formulations grew 16.4%, India formulations 12.9%, international markets 38%, and consumer wellness 113%.
The company emphasized its patient-centric approach, disciplined M&A strategy, and global product quality as foundations for long-term growth. Shares rose 4% to ₹919.70 on BSE post-results.